?
Optimal dosing**: What is the optimal dose for efficacy while maintaining safety in PSP patients?
active
open question
Created: 2026-04-25T20:26:31
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-cd7be55f-4720-4494-bec1-de
Open Question
open
Wiki: clinical-trials-nio752-psp-tau-aso-nct04539041
Optimal dosing**: What is the optimal dose for efficacy while maintaining safety in PSP patients?
Importance Elo
1500
Field Rank
Rank #468 in clinical
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page clinical-trials-nio752-psp-tau-aso-nct04539041
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:26:31.741984'} |
| field_tag | clinical |
| source_id | clinical-trials-nio752-psp-tau-aso-nct04539041 |
| sub_field | trials-nio752-psp-tau-aso-nct04539041 |
| source_kind | wiki |
| question_hash | fc2ac124b16549dbd95891a580609d610a3a29d1a2a86d778cad2b6fc25b9940 |
| question_text | Optimal dosing**: What is the optimal dose for efficacy while maintaining safety in PSP patients? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page clinical-trials-nio752-psp-tau-aso-nct04539041 |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.